Argel Aguilar Valles
@argelaguilarvalles.bsky.social
700 followers 420 following 100 posts
Associate Professor of Neuroscience at Carleton University. Proud Mexican living in Canada. Alumni from McGill University, Scripps Institute and UNAM
Posts Media Videos Starter Packs
Reposted by Argel Aguilar Valles
ramosneuro.bsky.social
People in my life keep talking about waiting out the Trump presidency.

I’m trying to tell them that the Trump regime is doing things you do when you have no intention of surrendering power.
Reposted by Argel Aguilar Valles
carmensandi10.bsky.social
Very happy to share our new paper in Biological Psychiatry, showing that Urolithin A reverses high anxiety by repairing mitochondrial function in the nucleus accumbens.

Big kudos to first co-authors David Mallet & Doğukan Ülgen, our amazing team, and collaborators!

🔗 Paper: doi.org/10.1016/j.bi...
Redirecting
doi.org
Reposted by Argel Aguilar Valles
mayoonthebrain.bsky.social
Congrats to @pact-lab.bsky.social PhD student @anadeutsch.bsky.social on her 1st first-author paper from the lab! 🎉

She explored how MDMA & methamphetamine impact cortisol, endocannabinoids, & BDNF levels in healthy humans and how this relates to the subjective drug experience 💊👇
The effect of methamphetamine and 3,4-methylenedioxymethamphetamine on peripheral endocannabinoid concentrations: a study in healthy adults - Psychopharmacology
Rationale Stimulant drugs such as methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA) can impact neurobiological systems implicated in stress, reward processing, and drug use. Although recent preclinical evidence implicates the endocannabinoid (eCB) system in these processes, little is known about the acute effects of stimulants on eCB levels in humans. Objectives The aim of the present study was to investigate the effects of acute administration of the prototypical psychostimulant MA and the psychostimulant-empathogen MDMA on circulating eCB levels in healthy adults. Methods Using a within-subject, double-blind design, this study assessed the acute effects of MA (20 mg), MDMA (100 mg), and placebo on plasma eCB levels in healthy human participants (N = 22) during three separate sessions. Blood samples assessing concentrations of the eCBs anandamide (AEA) and 2-Arachidonoylglycerol (2-AG) were collected between 150- and 180-minutes post-drug administration, and subjective measures of drug effects were collected at regular intervals. Results MA, but not MDMA, was associated with significantly lower 2-AG plasma concentrations compared to placebo. Neither drug impacted AEA concentrations. However, during the placebo condition, higher AEA concentrations were correlated with disliking the ‘drug effects’, suggesting a possible relationship between AEA levels and negative expectations of subjective drug effects. Conclusions These findings provide novel insights into how stimulant drugs act on the eCB system and may help to develop treatments for SUDs.
link.springer.com
Reposted by Argel Aguilar Valles
franklandlab.bsky.social
New paper from the lab led by Ali Golbabaei. If you’re interested in systems consolidation, generalization and hippocampal neurogenesis a short 🧵 follows:

authors.elsevier.com/a/1lsO73QW8S...
authors.elsevier.com
Reposted by Argel Aguilar Valles
deryasargin.bsky.social
As our graduate program deadline approaches, we are recruiting motivated students to join our team. See details below:
canacn.bsky.social
New ad: Graduate (MSc / PhD) Student Positions – Neurophysiology of Autism Mouse Models – University of Calgary can-acn.org/graduate-msc... @deryasargin.bsky.social #neurojobs
Reposted by Argel Aguilar Valles
veronicachelu.bsky.social
Tomorrow, Sept 19 | 3:30 PM, at #CCNP2025 (ccnp.ca) in Montreal, I’ll be co-chairing the symposium “Psychedelics & Psychiatry” 🍄🧠 with @swubat.bsky.social.

We’ll explore how psychedelics reshape brain circuits & behavior, bridging preclinical & clinical perspectives.
Canadian College of Neuropsychopharmacology
ccnp.ca
Reposted by Argel Aguilar Valles
mark-carney.bsky.social
Just arrived in Mexico City.
 
In today’s rapidly shifting global landscape, we’re focused on deepening our relationship with Mexico to create good careers for our workers, strengthen supply chains, and build economic resilience across our nations.
Reposted by Argel Aguilar Valles
carmensandi10.bsky.social
Wonderful to have had you with us for your sabbatical at @epfl-brainmind.bsky.social, @argelaguilarvalles.bsky.social! Many thanks for all the exchanges, your input to our projects and your great talk! & Looking forward to continuing our collaboration!
argelaguilarvalles.bsky.social
Wrapping up a short sabbatical visit to @carmensandi10.bsky.social's lab at @epfl-brainmind.bsky.social — an inspiring experience supported by the Swiss National Science Foundation @snsf.ch 🙏.
argelaguilarvalles.bsky.social
Grateful for the hospitality, the stimulating discussions, and the collaborative spirit that makes science thrive. Looking forward to what’s next! 🚀
argelaguilarvalles.bsky.social
Added bonus: networking with trainees & researchers from the @fens.org–CHEN–NeuroLéman Summer School, and wonderful conversations with visiting scientist Mootaz Salman!
argelaguilarvalles.bsky.social
We had a rich exchange of ideas, paving the way for exciting future collaborations. I also had the chance to interact with Carmen’s talented team — their work and enthusiasm are truly impressive!
argelaguilarvalles.bsky.social
Wrapping up a short sabbatical visit to @carmensandi10.bsky.social's lab at @epfl-brainmind.bsky.social — an inspiring experience supported by the Swiss National Science Foundation @snsf.ch 🙏.
Reposted by Argel Aguilar Valles
tylerekins.bsky.social
Excited to share our latest publication -- psychedelic drugs can enhance synaptic connectivity of neurons not expressing 5-HT2ARs (but requiring 5-HT2AR expression in the input neurons -- lots in the supplementals too!)

www.nature.com/articles/s41...
Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors - Molecular Psychiatry
Molecular Psychiatry - Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors
www.nature.com
Reposted by Argel Aguilar Valles
alleninstitute.org
Happy birthday to us! 🥳

In 2003, we launched with just four employees in a small, rented laboratory working together towards a big goal - map the entire mammalian brain in a way the world had never seen.

🧠📈 #OpenScienceWeek
argelaguilarvalles.bsky.social
Negroni Sbagliato… with prosecco in it… stunnin’
Reposted by Argel Aguilar Valles
lucieberko.bsky.social
🎙️ I am very proud to have participated (with a very strong French accent) to the BBC Radio 4 program Understand entitled "The Trip", about the science, culture, history and future of psychedelics 🌈

www.bbc.co.uk/programmes/m...
argelaguilarvalles.bsky.social
Superb talk indeed! Fascinating models!
carmensandi10.bsky.social
Great Seminar today at @epfl-brainmind.bsky.social with Mootaz Salman (Oxford, UK) @oxforddpag.bsky.social
We learned how blood-brain barrier dysfunction drives neurodegenerative disease & how 3D BBB-on-a-chip models uncover new therapeutic targets
Many thanks for the highly inspiring talk!
Reposted by Argel Aguilar Valles
carmensandi10.bsky.social
Great Seminar today at @epfl-brainmind.bsky.social with Mootaz Salman (Oxford, UK) @oxforddpag.bsky.social
We learned how blood-brain barrier dysfunction drives neurodegenerative disease & how 3D BBB-on-a-chip models uncover new therapeutic targets
Many thanks for the highly inspiring talk!
Reposted by Argel Aguilar Valles
nidhise.bsky.social
In Nov last year, we published a predictive theory of locomotor adaptation to novel environments, capturing learning and generalization phenomena in over ten experiments:
www.nature.com/articles/s41...

I'm honored to be featured on the 2025 Innovators Under 35 list for this work.
ter.li/7c0jek
Reposted by Argel Aguilar Valles
drjkhokhar.bsky.social
Excited to share our development of a novel model of TMD pain lead by @daspainbrain.bsky.social with @andpru.bsky.social!
biorxivpreprint.bsky.social
Developing a model of temporomandibular disorder in the common marmoset using nerve growth factor https://www.biorxiv.org/content/10.1101/2025.08.20.671273v1